Takeda Pharmaceutical Co. Ltd. has introduced a line of products for lysosomal storage disorders in India, signalling early efforts by the Japanese company to dip into the ex-Shire PLC portfolio and step up momentum for the post-merger operation in the country.
Takeda, which completed its $62bn acquisition of Shire in January this year, said that it had introduced idursulfase (available as...







